@article{a02a5a5686884498af8f2e22f732573e,
title = "The relationship between interleukin-6 and functional connectivity in methamphetamine users",
abstract = "Methamphetamine (MA) causes an increase in pro-inflammatory cytokines in animal models and in humans. Resulting activation of microglia and neuro-inflammation could, via effects on reward networks, mediate behavioral characteristics of addiction. We examined the relationship between interleukin-6 (IL-6) and corticolimbic and striatolimbic resting-state functional connectivity (RSFC). Thirty adults diagnosed with MA dependence and 20 control subjects underwent a resting-state functional magnetic resonance imaging (fMRI) scan and gave a blood sample for determination of plasma IL-6 levels. Seed-based RSFC analyses were performed to examine the interactive effect of group and IL-6 on ventral striatal and prefrontal connectivity. Within the MA group, IL-6 levels were positively related to striatolimbic RSFC but negatively related to corticostriatal RSFC. Our findings with IL-6 support the idea that inflammation may at least partly mediate the link among MA use disorder, RSFC, and behavior, possibly via effects on mesolimbic and mesocortical dopaminergic systems.",
keywords = "Corticostriatal, IL-6, Inflammation, Mesocorticolimbic, Methamphetamine, Resting-state functional connectivity",
author = "Milky Kohno and Loftis, {Jennifer M.} and Marilyn Huckans and Dennis, {Laura E.} and Holly McCready and Hoffman, {William F.}",
note = "Funding Information: This work was supported in part by NIAAAR21AA020039 (WFH); Department of Veterans Affairs Clinical Sciences Research and Development Merit Review Program, I0CX001558 (WFH); Department of Veterans Affairs Biomedical Laboratory Research and Development Merit Review Program, 1I01BX002061 (JML); DOJ 2010-DD-BX-0517 (WFH); NIDAP50DA018165 (WFH, JML); Oregon Clinical and Translational Research Institute (OCTRI), 1 UL1 RR024140 01 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research. Dr. Kohno was supported by NIDAT32 DA007262 and NIAAAT32 AA007468. We thank Dr. Marilyn Huckans and the staffs of the VAPORHCS Substance Abuse Treatment Program, CODA Treatment Recovery and Volunteers of America Residential Treatment Centers, Portland, OR for their help and recruitment efforts. We appreciate Dr. Aaron Janowsky's comments on the manuscript. Funding Information: This work was supported in part by NIAAA R21AA020039 (WFH); Department of Veterans Affairs Clinical Sciences Research and Development Merit Review Program , I0CX001558 (WFH); Department of Veterans Affairs Biomedical Laboratory Research and Development Merit Review Program , 1I01BX002061 (JML); DOJ 2010-DD-BX-0517 (WFH); NIDA P50DA018165 (WFH, JML); Oregon Clinical and Translational Research Institute (OCTRI) , 1 UL1 RR024140 01 from the National Center for Research Resources (NCRR) , a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research. Dr. Kohno was supported by NIDA T32 DA007262 and NIAAA T32 AA007468 . We thank Dr. Marilyn Huckans and the staffs of the VAPORHCS Substance Abuse Treatment Program, CODA Treatment Recovery and Volunteers of America Residential Treatment Centers, Portland, OR for their help and recruitment efforts. We appreciate Dr. Aaron Janowsky{\textquoteright}s comments on the manuscript. Publisher Copyright: {\textcopyright} 2018",
year = "2018",
month = jun,
day = "11",
doi = "10.1016/j.neulet.2018.04.037",
language = "English (US)",
volume = "677",
pages = "49--54",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
}